Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae represent a major 28 threat to human health. Here, we captured 288 3GC-R Enterobacteriaceae clinical isolates 29 from 258 patients presenting at a regional Australian hospital over a 14-month period.
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Coincidentally, the reverse primer sequence for our CMY assay was identical to one designed 167 previously [16] .
169
PCRs were carried out using 0.1 µM of the 16S probe, 0.2 µM of the 16S primers, TEM 170 primers and the CTX-1, CTX-9, and TEM probes, 0.3 µM of the SHV primers, and 0.4 µM of 171 the CTX-1, CTX-9, and CMY primers, and the SHV and CMY probes. Reactions contained 1X 172 Sso Advanced Universal Probes Supermix (Bio-Rad), primers, probes, 1 µL DNA template, 173 and molecular grade H2O to a 5 µL total reaction volume. PCRs were performed on a CFX96 
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Redesign of current ESBL PCR assays to improve specificity and detection rates. We next set 228 out to identify the abundance of 3GC-R AMR determinants in our isolate collection using 229 real-time PCR. The rapid expansion of WGS data in recent years has enabled improvements 230 to be made upon assays designed in the pre-WGS era, which risk being either non-specific or 231 intolerant to sequence diversity within enzyme families. Given a sufficiently large and 232 diverse dataset, sequence diversity can result in a non-trivial proportion of false-negative 233 calls, skewing epidemiological observations. Examination of previously published ESBL assays
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[30] identified several mismatches in primer/probe pairs, with the mismatches especially 235 problematic for the CTX-M enzymes (data not shown). To overcome issues with false-236 negative results using existing assays, we analyzed the extensive volume of publicly available 237 sequence data to identify conserved sequence regions suitable for assay design. Our 238 redesigned assays target the genes encoding the most common ESBLs (CTX-M group 1, CTX-239 M group 9), along with SHV and TEM β-lactamases, which can evolve to become ESBLs 240 through mutations in their active sites or contribute to clinically relevant AMR due to 241 increased expression.
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ESBL and β-lactamase prevalence in 3GC-R Enterobacteriaceae. Preliminary validation of our 244 newly designed PCR assays was performed to determine their accuracy and specificity. The 245 assays were first tested on a characterized set of 12 strains (Table S2 ) that have previously 246 been subjected to WGS [31]. Our assays showed 100% sensitivity and specificity for all 247 enzymes (CTX-M group 1, CTX-M group 9, CMY, SHV and TEM) according to corresponding 248 WGS data. Following this confirmation, our assays were run across the entire isolate set 249 (n=288) in pentaplex format (blaCTX-M-1 group, blaCTX-M-9 group, blaSHV, blaTEM, 16S rDNA; Figure   250 1), with blaCMY tested in singleplex format. Our assays performed well, with 100% 251 concordance between PCR genotypes and WGS of 98 isolates, and no false-negatives 252 identified. Overall, a β-lactamase genotype was identified in 277 (96.2%) isolates using PCR.
253
Consistent with the previously reported prevalence of 3GC-R enzymes in Australia and New 254 Zealand [10], we found that blaCTX-M-1 group was most common, being present in 144/288 255 (50%) isolates, including 105/231 (45.5%) E. coli and 36/49 (73.5%) K. pneumoniae isolates.
256
The blaCTX-M-9 group was next most common, being found in 93/288 (32.3%) isolates, 260 group genes were present in 4/8 (50%) and 0/8 (0%) of these isolates, respectively. The acquired ampC gene, blaCMY, was identified in 30/231 (13%) of E. coli, 3/49 (6.1%) of K. 
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Due to the conserved nature of our TEM and SHV assays to detect all enzyme variants, we 281 do not recommend these assays for identifying ESBL-conferring mutations in blaTEM or blaSHV; 282 rather, they can only be used to guide further diagnostic tests. However, the quantitative 283 nature of our pentaplex assay, which includes an internal 16S rDNA control, permits the 284 detection of copy number increases in the β-lactamase genes. By examining the cycles-to 285 threshold differences between 16S and blaTEM and blaSHV, we identified an ~8-10x copy 286 number increase in SCHI0016.S.139, which also possessed blaCTX-M-15. Consistent with this PCR result, WGS verified that this strain harbored a multicopy plasmid carrying blaTEM-135.
288
TEM-135 differs from TEM-1 by having a M182T mutation that confers improved β -289 lactamase stability and potential for third-generation cephalosporin hydrolysis and ESBL 290 activity [33] . Therefore, examining β-lactamase copy number is important when determining 291 ESBL potential from genetic or genomic data, particularly in strains where common ESBLs 292 are not identified.
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Correlation of blaCMY and cefoxitin resistance. Of the 81 isolates resistant to cefoxitin by 295 phenotypic methods, blaCMY was detected in only 31 (38.3%) cases. Resistance to cefoxitin is 296 often used as a surrogate marker for AmpC presence, although this approach is imperfect 297 [34] . This correlation is also dependent on the MIC, with higher MICs more reliably 298 predicting AmpC β-lactamase presence [34] . Our findings concur with this prior work, with 299 61.7% of isolates failing to amplify the blaCMY target, suggesting a lack of sensitivity in using 300 cefoxitin as a screening tool for AmpC enzymes. In support of this hypothesis, AmpC has 301 previously been reported as an underappreciated mechanism of 3GC-R due to a lack of 302 standardized testing for its detection [35] . As such, molecular methods such as PCR that can 
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Monitoring patient-to-patient spread in an intensive care unit. Fifty-four (18.8%) 3GC-R 329 isolates obtained during this study originated from ICU-admitted patients. Resistance to 330 ceftriaxone and cefoxitin was identified in 100% and 31.4% of isolates, respectively, and 331 meropenem resistance was identified in three (5.5%) isolates. Due to their dominance, only 332 E. coli and K. pneumoniae genomes were analyzed to assess for potential transmission 333 events. Among the E. coli population (Figure 2) 
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Population structure of E. coli and K. pneumoniae genomes. We subjected an additional 36 355 strains to WGS (total n=98) to capture a snapshot of genomic diversity and population 356 structure in our samples (Figures 2 and 3) . In silico MLST of the 79 genome-sequenced E. coli 357 strains found that ST131 was most common ST (n=11; 13.9%). This finding is consistent with 358 a recent study of the population structure of Australian, New Zealand, and Singaporean 359 multidrug-resistant E. coli isolates, where ST131 was identified as the dominant strain [10].
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The highly successful ST131 clone has spread worldwide, where it causes urinary tract and 361 bloodstream infections, particularly community-associated infections [38] . Overall, 362 depending on the country, ST131 accounts for 12-27% of all community-acquired E. coli 363 infections [39] . In addition, transmission events have been documented among hospitalized 364 patients, although person-to-person spread appears to be more important between household contacts [40] . Among our ST131 isolates, we found high frequencies of 366 fluoroquinolone resistance-conferring variants (GyrAS83L, GyrAD87N, and ParCS80I) alongside 367 frequent carriage of plasmid-borne CTX-M-14 (CTX-M-9 group) and CTX-M-15 (CTX-M-9 368 group) ESBLs. We also identified three strains belonging to the emerging multi-drug resistant 369 pandemic clone, ST1193: SCHI0016.S.133, SCHI0016.S.172 and SCHI0016.S.274, although the 370 latter strain was excluded from the phylogenetic analysis due to the presence of mixtures.
371
These isolates also possessed the same three fluoroquinolone-resistant SNPs as the ST131 372 strains. It has been proposed that ST1193 strains evolved fluoroquinolone resistance 373 relatively recently through multiple recombination events with other AMR E. coli strains 374 [41] .
376
Phylogenomic analysis of our 10 K. pneumoniae genomes identified several distinct lineages, 377 which comprised two ST14 strains and one each of ST17, ST307, ST309, ST395, ST656, ST697, 378 ST873, and ST969. Of note, the hypervirulent and globally disseminated ST258 clone, which 379 is responsible for a large number of hospital deaths [42], was not identified in our dataset.
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However, we identified another globally disseminated clone, ST395, which has also been 381 retrieved from clinical cases in Europe and Asia [43] . Concerningly, this ST395 isolate, 382 SCHI0016.S.137, carried both the ESBL genes blaSHV-11 and blaCTX-M-15 and the OXA-48-like 383 carbapenemase, blaOXA-232, the latter of which confers low-level meropenem resistance.
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This study had several recognized limitations. First, isolates were only collected from a 386 hospital setting rather than from both nosocomial and community sources. It is well-387 established that differences in AMR patterns and their associated molecular mechanisms 388 exist between hospital and community settings. Second, the absence of certain high-risk 389 populations within our hospital (e.g. solid organ or hematopoietic stem cell transplantation, 390 burns) limits the generalizability of our findings to other settings. Third, our PCR assays can only identify the presence or change in copy number of the most common ESBL and ampC 392 genes. Although these loci make up the majority (>90%) of β-lactamase enzymes present in 393 3GC-R Enterobacteriaceae, they do not capture all potential ESBLs, leaving less common 394 ESBL and ampC genes unidentified. In addition, PCR assays for blaTEM or blaSHV cannot 395 discriminate between ESBLs and non-ESBLs, with additional assays or concurrent WGS 396 required to confirm ESBL status. Our assays also cannot detect chromosomal changes 397 leading to AMR (e.g. porin mutations or efflux pump up-regulation), making these assays less 398 useful for 3GC-R bacteria that frequently encode these AMR determinants (e.g.
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Pseudomonas aeruginosa). One way to address detection issues is to undertake WGS on all 400 samples; however, as demonstrated in this study, some AMR determinants will likely remain 401 cryptic due to their novelty, thereby requiring additional functional work to verify their 402 causative nature. Fourth, our PCR was unable to distinguish whether β-lactamase genes 403 were present on low-copy plasmids or were chromosomally incorporated, which has 404 implications for AMR transmissibility between and among bacterial populations. Finally,
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~40% of samples were obtained from rectal swabs, which have inherent limitations in 406 detection of multidrug-resistant organisms due to the high microbial burden from this 407 specimen type coupled with difficulties in adequate sample collection. It is therefore likely 408 that we did not capture all 3GC-R clinical isolates during our study period due to the 409 inherent difficulties associated with this sampling technique, and thus may have missed 410 potential transmission events in the hospital. 
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Sequence type (ST)131 is indicated by the gray-shaded box; strains isolated from intensive 442 care unit patients are highlighted in green. . coli (n=231) K. pneumoniae (n=49) K. aerogenes (n=1) K. oxytoca (n=3) E. cloacae (n=4 27 (11.7%) 3 (6.1%) 1 (100%) 1 (33.3%) 0 (0%) ESBL and ampC gene prevalence blaCTX-M-1 104 (45.0%) 36 (73.5%) 0 (0%) 2 (66.7%) 2 (50.0%) blaCTX-M-9 89 (38.5%) 4 (8.2%) 0 (0%) 0 (0%) 0 (0%) blaSHV 9 (3.9%) 38 (77.6%) 0 (0%) 0 (0%) 1 (25.0%) blaTEM 93 (40.3%) 33 (67.3%) 0 (0%) 2 (66.7%) 2 (50.0%) blaCMY 30 (13.0%) 3 (6.1%) 0 (0%) 0 (0%) 1 (25.0%) PCR-negative c 7 (3.0%) 1 (4%) 1 (100%) 1 (33.3%) 1 (25.0%) a Antimicrobial susceptibility testing performed by automated method (VITEK 2®) and EUCAST breakpoints applied 583 b ESBL phenotypic testing performed by disc diffusion method 584 c DNA integrity was confirmed by 16S rDNA PCR [15] , which forms part of the pentaplex assay. Three PCR negative E. coli strains encoded blaDHA-1, one E. 585 cloacae encoded blaACT-17, one K. oxytoca encoded a blaOXY-2-1, a second K. oxytoca (included as a mixture with K. pneumoniae) encoded blaOXY-2-4, and 5/11 586 isolates had no β-lactamases identified despite whole-genome sequencing.
